Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exact Sciences Corp. filings document the regulatory record of a cancer diagnostics company whose public-company disclosures included material events, shareholder voting matters, capital structure, clinical and regulatory updates, operating results, and governance matters. The company’s securities disclosures identify common stock, convertible senior notes, and shelf-registered securities categories.
Recent filings also document corporate-status changes for EXAS, including Nasdaq removal from listing and registration for the common stock and a Form 15 certification covering termination or suspension of Exchange Act reporting duties. Related material-event reports and proxy materials describe transaction agreements, stockholder voting, litigation-related disclosures, and risk factors tied to the company’s public reporting transition.
Exact Sciences director Shacey Petrovic reported disposing of all common stock holdings in connection with the closing of Exact Sciences’ merger with Abbott Laboratories. The Form 4 shows issuer dispositions of 16,406 and 5,398 directly held shares, plus 7,095 shares held indirectly in a grantor retained annuity trust.
According to the merger terms, at the effective time each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares outstanding immediately before the merger became fully vested, were cancelled, and likewise converted into the cash merger consideration (less any applicable tax withholding).
EXACT Sciences Corp director Katherine S. Zanotti reported disposing of all her common stock in connection with the company’s acquisition by Abbott Laboratories. On March 23, 2026, Badger Merger Sub I, Inc. merged with Exact Sciences, leaving Exact as a wholly owned Abbott subsidiary.
At the merger’s effective time, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. Zanotti’s 55,361 shares, plus an additional 5,398 shares, were cancelled and converted into the cash merger consideration, leaving her with no remaining Exact Sciences holdings. All restricted shares under company plans became fully vested and were also converted into the same cash amount per share, net of any tax withholding.
EXACT SCIENCES CORP director Kimberly J. Popovits reported the disposition of her remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, Exact Sciences became a wholly owned subsidiary of Abbott under a previously signed merger agreement.
At the effective time of the merger, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares subject to vesting or other restrictions were deemed fully vested, cancelled, and similarly converted into the cash merger consideration, leaving Popovits with no remaining Exact Sciences common stock.
Exact Sciences Corp director James Edward Doyle reported disposing of his remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, 52,564 shares of Exact Sciences common stock were returned to the issuer, leaving 5,398 shares. A second disposition of 5,398 shares reduced his direct holdings to zero. Under the merger agreement, each Exact Sciences share outstanding at the effective time was converted into the right to receive $105.00 in cash, and restricted shares became fully vested and cancelled for the same cash consideration, less applicable tax withholding.
Exact Sciences director Paul J. Clancy disposed of his common stock in connection with the company’s cash merger with Abbott Laboratories. On March 23, 2026, he reported issuer dispositions totaling 26,038 shares of common stock, leaving him with zero shares after the transactions.
Under the merger agreement, each Exact Sciences share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Shares of common stock that were subject to vesting or other restrictions under company stock plans were deemed fully vested at the effective time, then cancelled and converted into the same cash merger consideration, less any applicable tax withholding.
Exact Sciences Corporation director Michael J. Barber reported disposing of all his company equity in connection with the closing of a cash merger with Abbott Laboratories. At the merger’s effective time, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest, under the Merger Agreement.
All restricted common stock and each deferred stock unit became fully vested, then were cancelled and converted into the right to receive the same $105.00 cash consideration per underlying share, less applicable tax withholding. Barber’s Form 4 shows issuer dispositions of deferred stock units and common stock, leaving him with no remaining Exact Sciences shares or deferred stock units.
EXACT SCIENCES CORP director Leslie Trigg disposed of all her directly held common shares back to the company in connection with its cash merger with Abbott Laboratories. One transaction returned 3,244 shares and a second returned 13,925 shares, leaving her with zero shares afterward.
Under the merger terms, each Exact Sciences common share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Stock awards subject to vesting or other restrictions were also deemed fully vested, cancelled and converted into the same cash consideration, less applicable tax withholding.
Exact Sciences Corp notified the Nasdaq Stock Market LLC of a removal of its Common Stock from listing and registration pursuant to Form 25. The exchange certified it complied with 17 CFR 240.12d2-2 and the issuer complied with exchange rules governing voluntary withdrawal.
The filing is an administrative notice of delisting/withdrawal under Section 12(b) of the Exchange Act and does not state transaction amounts, proceeds, or timing beyond the regulatory certification.
Exact Sciences Corporation has been acquired by Abbott Laboratories and is now a direct, wholly owned subsidiary of Abbott. In the merger, each share of Exact common stock (other than dissenting and certain excluded shares) was converted into the right to receive $105.00 in cash, less applicable withholding taxes, resulting in total merger consideration of approximately $21 billion.
Following the merger, Exact’s common stock will be delisted from Nasdaq, and Exact plans to deregister its shares and suspend SEC reporting. Exact also repaid in full all obligations under its 2025 credit agreement. For holders of Exact’s various convertible notes due 2027, 2028, 2030 and 2031, the merger changed each note so that each $1,000 principal amount is now convertible solely into cash equal to the applicable conversion rate multiplied by $105.00. Exact’s prior board members and officers resigned at the effective time, and its certificate of incorporation and bylaws were amended and restated.
Exact Sciences Corporation reports that all regulatory approvals and clearances needed to complete its planned merger with Abbott Laboratories have been obtained. Exact’s stockholders had previously approved the transaction at a special meeting on February 20, 2026. The merger, under which Exact will become a direct, wholly owned subsidiary of Abbott, is anticipated to close on March 23, 2026, subject to satisfaction or waiver of the remaining conditions in the merger agreement. The company also highlights typical merger-related risks, including potential delays, termination scenarios, transaction costs, business disruption, and possible litigation.